R. Stone

Publications123
h-index15
Citations833
Highly Influential Citations39
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • C. Bloomfield
  • 803 Publications, 79,072 Citations
  • R. Larson
  • 554 Publications, 67,321 Citations
  • S. Faderl
  • 555 Publications, 30,414 Citations
  • F. Ravandi
  • 1,337 Publications, 29,870 Citations
  • Publications
  • Influence
A Human Trigger for the Great Quake of Sichuan?
SEISMOLOGYThe first researchers have gone public with evidence that stresses from water piled behind the new Zipingpu Dam may have triggered last May's devastating earthquake in China's Sichuan… Expand
  • 67
  • 9
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative…
  • 44
  • 6
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic…
  • 57
  • 4
Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy
Background:While midostaurin, a pan-kinase inhibitor, represents an advance in the treatment of newly diagnosed patients Methods: Results from 29 patients in the trial (n=44) who were ≤60 years old… Expand
  • 30
  • 3
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic…
  • 17
  • 3
A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.
GO is a calicheamycin toxin-conjugated humanized monoclonal antibody with specificity for the CD33 antigen expressed on blasts from 90% of AML pts and is approved for single agent use in… Expand
  • 6
  • 2
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia…
The prognosis of elderly patients (pts) with acute lymphoblastic leukemia (ALL) remains poor, and novel therapeutic approaches are clearly needed. CD19 is expressed on the majority of precursor-B… Expand
  • 24
  • 1
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Gail J Roboz1, Courtney D DiNardo2, Eytan M Stein3, Stéphane de Botton4, Alice S Mims5, Gabrielle T Prince6, Jessica K Altman7, Martha L Arellano8, Will Donnellan9, Harry P Erba10, Gabriel N… Expand
  • 26
  • 1
Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial…
Among the prognostic cytogenetic and molecular aberrations in AML, t(8;21)(q22;q22) and inv(16)(p13q22) and their corresponding molecular rearrangements RUNX1/RUNX1T1 and CBFB/MYH11 (each involving a… Expand
  • 27
  • 1
A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial
Background: Current chemotherapy regimens in children with ALL produce disease-free survival (DFS) rates of greater than 80%. In contrast, adults with ALL have a much poorer prognosis, with DFS rates… Expand
  • 26
  • 1